ArticleInternational journal of epidemiology2019
Comparative validation of an epigenetic mortality risk score with three aging biomarkers for predicting mortality risks among older adult males.
Article in International journal of epidemiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Epigenetic Ageing and Breast Cancer Risk: A Systematic Review.Cancer medicine · 2024Pooled it
- Molecular markers, mechanisms and metrics of biological aging: a scoping review.Frontiers in aging · 2026Review
- Pubertal timing as a predictor of epigenetic aging and mortality risk in young adulthood.Developmental psychology · 2025Article
- Methylation and algorithms in biological aging: a scoping review.Frontiers in aging · 2025Review
- Epigenetic age acceleration and risk of aortic valve stenosis: a bidirectional Mendelian randomization study.Clinical epigenetics · 2024Article
- Integrating DNA Methylation Measures of Biological Aging into Social Determinants of Health Research.Current environmental health reports · 2022Review
- Article
- DNAm-based signatures of accelerated aging and mortality in blood are associated with low renal function.Clinical epigenetics · 2021Article
- Epigenetic age acceleration is associated with cardiometabolic risk factors and clinical cardiovascular disease risk scores in African Americans.Clinical epigenetics · 2021Article
- Blood-derived DNA methylation predictors of mortality discriminate tumor and healthy tissue in multiple organs.Molecular oncology · 2020Article
- Article
- Article
- Short-term ambient particle radioactivity level and renal function in older men: Insight from the Normative Aging Study.Environment international · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundA 'mortality risk score' (MS) based on ten prominent mortality-related cytosine-phosphate-guanine (CpG) sites was previously associated with all-cause mortality, but has not been verified externally. We aimed to validate the association of MS with mortality and to compare MS with three aging biomarkers: telomere length (TL), DNA methylation age (DNAmAge) and phenotypic age (DNAmPhenoAge) to explore whether MS can serve as a reliable measure of biological aging and mortality.
methodsAmong 534 males aged 55-85 years from the US Normative Aging Study, the MS, DNAmAge and DNAmPhenoAge were derived from blood DNA methylation profiles from the Illumina HumanMethylation450 BeadChip, and TL was measured by quantitative real-time polymerase chain reaction (qRT-PCR).
resultsA total of 147 participants died during a median follow-up of 9.4 years. The MS showed strong associations with all-cause, cardiovascular disease (CVD) and cancer mortality. After controlling for all potential covariates, participants with high MS (>5 CpG sites with aberrant methylation) had almost 4-fold all-cause mortality (hazard ratio: 3.84, 95% confidence interval: 1.92-7.67) compared with participants with a low MS (0-1 CpG site with aberrant methylation). Similar patterns were observed with respect to CVD and cancer mortality. MS was associated with TL and DNAmPhenoAge acceleration but not with DNAmAge acceleration. Although the MS and DNAmPhenoAge acceleration were independently associated with all-cause mortality, the former exhibited a higher predictive accuracy of mortality than the latter.
conclusionsMS has the potential to be a prominent predictor of mortality that could enhance survival prediction in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.